Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Polycystic Ovary Syndrome 7Neoplasms 3Melanoma 3Urinary Bladder Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Prostatic Neoplasms 2Ovarian Neoplasms 2Obesity 2Infertility 2Glioblastoma 2Endometrial Neoplasms 2Breast Neoplasms 2Adenocarcinoma Of Esophagus 2Uterine Cervical Neoplasms 1TP53 Y220C Mutation 1Sarcoma, Ewing 1Sarcoma 1Prostate Cancer Recurrent 1Progression-Free Survival 1Preleukemia 1Posterior Fossa Ependymal Tumor 1Osteosarcoma 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms by Site 1Metabolic Diseases 1Medulloblastoma 1Leukoplakia, Oral 1Leukemia, Myeloid, Acute 1Insulin Resistance 1Hyperandrogenism 1

Interventions

Metformin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Progression-Free Survival × Metformin × Clear all
NCT06826092 2025-02-13

Metformin for the Treatment of mCRC Patients Undergoing FOLFIRI Plus Target Therapy

Kaohsiung Medical University Chung-Ho Memorial Hospital

Phase 2 Recruiting
110 enrolled

Progression-Free Survival

Data powered by HemOnc (CC BY 4.0) Colophon âš¡